Literature DB >> 18047806

Inhibitory properties of nerve-specific human glutamate dehydrogenase isozyme by chloroquine.

Myung-Min Choi1, Eun-A Kim, Soo Young Choi, Tae Ue Kim, Sung-Woo Cho, Seung-Ju Yang.   

Abstract

Human glutamate dehydrogenase exists in hGDH1 (housekeeping isozyme) and in hGDH2 (nerve-specific isozyme), which differ markedly in their allosteric regulation. In the nervous system, GDH is enriched in astrocytes and is important for recycling glutamate, a major excitatory neurotransmitter during neurotransmission. Chloroquine has been known to be a potent inhibitor of house-keeping GDH1 in permeabilized liver and kidney-cortex of rabbit. However, the effects of chloroquine on nerve-specific GDH2 have not been reported yet. In the present study, we have investigated the effects of chloroquine on hGDH2 at various conditions and showed that chloroquine could inhibit the activity of hGDH2 at dose-dependent manner. Studies of the chloroquine inhibition on enzyme activity revealed that hGDH2 was relatively less sensitive to chloroquine inhibition than house-keeping hGDH1. Incubation of hGDH2 was uncompetitive with respect of NADH and non-competitive with respect of 2-oxoglutarate. The inhibitory effect of chloroquine on hGDH2 was abolished, although in part, by the presence of ADP and L-leucine, whereas GTP did not change the sensitivity to chloroquine inhibition. Our results show a possibility that chloroquine may be used in regulating GDH activity and subsequently glutamate concentration in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047806     DOI: 10.5483/bmbrep.2007.40.6.1077

Source DB:  PubMed          Journal:  J Biochem Mol Biol        ISSN: 1225-8687


  9 in total

1.  Simultaneous activation and inhibition of autophagy sensitizes cancer cells to chemotherapy.

Authors:  Kwan-Hwa Chi; Yu-Shan Wang; Yi-Chun Huang; Hsin-Chien Chiang; Mau-Shin Chi; Chau-Hwa Chi; Hsin-Ell Wang; Shang-Jyh Kao
Journal:  Oncotarget       Date:  2016-09-06

2.  Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Authors:  Ciska Verbaanderd; Hannelore Maes; Marco B Schaaf; Vikas P Sukhatme; Pan Pantziarka; Vidula Sukhatme; Patrizia Agostinis; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2017-11-23

3.  Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Authors:  Elisabeth F P Peterse; Bertine Niessen; Ruben D Addie; Yvonne de Jong; Arjen H G Cleven; Alwine B Kruisselbrink; Brendy E W M van den Akker; Remco J Molenaar; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Br J Cancer       Date:  2018-03-26       Impact factor: 9.075

Review 4.  Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables.

Authors:  Patrick Weyerhäuser; Sven R Kantelhardt; Ella L Kim
Journal:  Front Oncol       Date:  2018-08-27       Impact factor: 6.244

Review 5.  Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.

Authors:  Ashutosh M Shukla; Aparna Wagle Shukla
Journal:  Drugs Context       Date:  2019-11-25

Review 6.  Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.

Authors:  Ingvild Comfort Hvinden; Tom Cadoux-Hudson; Christopher J Schofield; James S O McCullagh
Journal:  Cell Rep Med       Date:  2021-12-21

7.  A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.

Authors:  Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

8.  Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Authors:  Remco J Molenaar; Robert J S Coelen; Mohammed Khurshed; Eva Roos; Matthan W A Caan; Myra E van Linde; Mathilde Kouwenhoven; Jos A M Bramer; Judith V M G Bovée; Ron A Mathôt; Heinz-Josef Klümpen; Hanneke W M van Laarhoven; Cornelis J F van Noorden; W Peter Vandertop; Hans Gelderblom; Thomas M van Gulik; Johanna W Wilmink
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 3.006

9.  Chloroquine commonly induces hormetic dose responses.

Authors:  Edward J Calabrese; Jaap C Hanekamp; Yannic N Hanekamp; Rachna Kapoor; Gaurav Dhawan; Evgenios Agathokleous
Journal:  Sci Total Environ       Date:  2020-09-25       Impact factor: 7.963

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.